Business News • PR NewsWire • CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia

CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia

CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia

SUZHOU, China, Dec. 12, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received the approval from the Human Research Ethics Committee (HREC) in Australia, and the acknowledgement from Australia's...

View More : https://www.prnewswire.com:443/news-releases/cstone-completes-registration-filing-for-the-phase-i-trial-of-its-tumor-imm...

Releted News by prnewswire

Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial

Castellum Acquires Properties in Central Västerås